New Dimebon Trials Launched

Contributed by: Dennis Fortier, President, Medical Care Corporation
________________________________________________

As we have chronicled in past posts, there are multiple agents for treating Alzheimer's disease in the FDA pipeline. One of the most advanced, and by many measures, most promising, is Dimebon.

The co-developers of this agent (Pfizer and Medivation) have announced two additional trials that are now enrolling subjects. While it is not completely understood, Dimebon appears to have a novel mechanism compared to the currently approved drugs Aricept, Razadyne, and Exelon, all of which are cholinesterase inhibitors and Namenda, which is a glutamate blocker. The mechanism is theorized to be one of improving mitochondrial function to promote ongoing cell health. The new trials will explore poly-therapy with Aricept and with Namenda.

To learn more details and to inquire about enrolling in the studies, please follow these links to the CONTACT study (or email contactstudy@medivation.com) and to the CONSTELLATION study (or call 1-877-377-4476).